Merck KGaA stays positive on CDMO arm’s future despite first-quarter slump
Merck KGaA’s revenue from its CDMO arm dropped in the first quarter due to customer destocking, but it still expects business to pick up in the second half of the year due to the timing of customer...
View ArticleClik here to view.
Researchers consider why Wegovy provides heart benefits beyond weight loss
The cardiovascular benefits of Novo Nordisk’s blockbuster weight loss drug Wegovy are not dependent on the amount of weight patients lost, according to a new analysis. The findings from the analysis of...
View ArticleClik here to view.
GoodRx gets back in Kroger's good graces, will work directly with grocer
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) GoodRx said on Wednesday that it has won back its relationship with Kroger to offer prescription...
View ArticleAdaptimmune’s debt financing deal; Tenaya to cut workers
Plus, news about Brixton Biosciences, Merck KGaA, Medincell, CellProthera and GSK: Adaptimmune inks up to $125M debt financing: The biotech gets $25 million to start as it prepares for a commercial...
View ArticleICER raises questions over Lykos’ MDMA studies as adcomm looms
The Institute for Clinical and Economic Review said it cannot fairly judge Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder because of concerns about certain elements of its...
View ArticleClik here to view.
LG spins off a new business that bets big on health software
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Electronics giant LG on Monday launched a spinoff business in a bid to branch out and make money from...
View ArticleClik here to view.
House committee advances bipartisan bill targeting Chinese biotech suppliers
A bill that would effectively force dozens of biopharma companies to cut ties with WuXi AppTec and four other Chinese biotech suppliers by 2032 advanced with bipartisan support in the House Oversight...
View ArticleWHO prequalifies Takeda's dengue vaccine Qdenga
The World Health Organization prequalified Takeda’s new dengue vaccine on Wednesday, a year after the company withdrew its FDA application for the candidate — though the company now says it will soon...
View ArticleEli Lilly settles with medical spa over its marketing of compounded tirzepatide
Eli Lilly reached a settlement with a South Carolina medical spa, marking a win in a broader legal campaign against how compounders have marketed versions of its diabetes and weight loss products....
View ArticleBeiGene looks at new partnerships, with a full cancer pipeline and growing...
Less than a year after the end of a PD-1 deal with Novartis, BeiGene is looking at new partnerships that could bring in new assets it could develop or commercialize, or out-license some of its...
View ArticleClik here to view.
Aiming to decentralize CAR-T manufacturing, Galapagos partners with largest...
Galapagos is teaming up with the US’s largest blood supply group to try to establish a nationwide network of decentralized CAR-T manufacturing. The partnership with Blood Centers of America, or BCA,...
View ArticleRoche teases 'encouraging' Phase 1 data for weight loss drug from $2.7B...
Roche offered a glimpse at promising early efficacy data on Thursday morning from a GLP-1/GIP agonist it obtained as part of its $2.7 billion acquisition of Carmot Therapeutics. In a Phase 1 trial...
View ArticleGastroparesis biotech CinDome secures $40M for path to pivotal trial
A gastroparesis biotech from the creator of CinCor Pharma, the hypertension biotech bought by AstraZeneca for $1.8 billion last year, has raised an additional $40 million to get through Phase 2 and...
View ArticleClik here to view.
GSK, UK government budget £130M to fight global antimicrobial resistance
GSK and the UK government have pledged £130 million ($165 million) to tackle antimicrobial resistance (AMR) at home and abroad by improving access to existing medicines and diagnostic tools. GSK said...
View ArticleLilly touts topline late-phase data for once-weekly insulin in race to enter...
As Novo Nordisk stares down an FDA adcomm later this month to discuss its once-weekly insulin, Eli Lilly is working on its own, sharing positive topline data from two Phase 3 studies for its insulin...
View ArticleClik here to view.
J&J makes small I&I acquisition to enter competitive IL-13, TSLP arena
Johnson & Johnson said Thursday it will pay $850 million in cash for Proteologix, a relatively unknown private biotech working on treatments for immune-mediated diseases, including the crowded...
View ArticleAstraZeneca's successor to Covid blockbuster Evusheld succeeds in Phase 3 trial
AstraZeneca’s latest antibody to prevent Covid-19 hit on both of its primary endpoints in a large Phase 3 trial, the UK company said Thursday. The preventive treatment known as sipavibart, which will...
View ArticleMonte Rosa’s $100M offering; Alexion to hand back preclinical program to...
Plus, news about First Wave BioPharma: Monte Rosa’s $100M offering: The molecular glue degrader biotech priced the offering at $4.70 per share $GLUE and expects it to close on May 20. At the end of...
View ArticleClik here to view.
Biogen and Ionis abandon ALS drug after disappointing early-stage trial
Biogen and Ionis are dropping an experimental treatment for amyotrophic lateral sclerosis, or ALS, a neurodegenerative disease in which people lose muscle control over time. The decision was based on...
View ArticleClik here to view.
Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
Pfizer and Arvinas’ targeted protein degrader plus Ibrance has shown promising efficacy in breast cancer patients in updated data from an early-stage trial, raising anticipation for a pair of ongoing...
View Article